February 4, 2019

Did Evolus Just Find the Fountain Of Youth?

Evolus Inc (EOLS) shares are up sharply today after the company gained FDA approval for their flagship product, Jeuveau, a cosmetic injection used to reduce the appearance of wrinkles on the face. This means Jeuveau is a direct competitor to Botox, which of course is a big seller for its parent company, Allergan. Here’s a recap.

about the author:

Mike Patton

Mike Patton took the leap into the markets beginning as a commodities broker in 2005, where he was responsible for identifying trading opportunities and executing trades on behalf of clients. After years as a broker he made the jump to education by joining the team at Trading Advantage, now Prosper Trading Academy.

Read Similar Articles

https://www.prospertrading.com/mike-shorr-live-qa-091826/Live Q&A with Mike Shorr: Allocation, Risk Management, and More
September 22, 2026

Live Q&A with Mike Shorr: Allocation, Risk Management, and More

Mike Shorr answers live trading room questions on triple witching, proper position allocation, and a faster ThinkorSwim trade execution setup.

Read Article
September 20, 2026

The Week Ahead: RISING PRICES

RISING PRICES The Dow, S&P 500, Nasdaq 100, and Russell 2000 all struggled this week, despite a Thursday rebound and an extremely muted triple witching expiration on Friday. Investors digested a Federal Reserve rate hike, a higher 10-year Treasury yield, renewed Iran-related energy risk, and fresh uncertainty around the AI investment cycle.  Geopolitics remains a major […]

Read Article
https://www.prospertrading.com/scott-bauer-ikbr-091626/The Fed Rate Hike: What Investors Should Know
September 18, 2026

The Fed Rate Hike: What Investors Should Know

Scott Bauer joins the IBKR Podcast to break down what matters most after the Fed’s latest hike, from Warsh’s tone to housing data and the October hike probability.

Read Article

Read Similar Articles

July 15, 2026

The Fed, Oil, and What Earnings Season Really Means

Scott Bauer joined the IBKR Podcast this week to break down what moved markets last week and what investors need to watch heading into the next stretch of earnings season. From lagging inflation data to big tech CapEx concerns, Scott did not hold back.

Read Article
July 5, 2026

The Week Ahead: Happy 250

The Dow rose more than ​1% to a record closing high on Thursday ahead of the long holiday weekend as a softer-than-expected U.S. ‌jobs report eased worries about interest rate hikes, while another sharp drop in chipmaker stocks weighed on the Nasdaq. The second half of 2026 kicked off this week much the same as […]

Read Article
June 28, 2026

The Week Ahead: Darn Inflation

A renewed sell-off in technology stocks grabbed headlines this week. The Nasdaq index fell 4.5%, closing lower 5 days in a row, led by a large 5.5% decline in the so-called Magnificent 7 mega cap names. Meanwhile, the post IPO exuberance around SpaceX appears to be fading, with shares now down 25% from their peak. […]

Read Article